

US009155334B2

(12) United States Patent

Moldoveanu et al.

(10) Patent No.:

US 9,155,334 B2

(45) **Date of Patent:**

*Oct. 13, 2015

(54) MODIFICATION OF BACTERIAL PROFILE OF TOBACCO

(71) Applicants: Serban C. Moldoveanu,

Winston-Salem, NC (US); Marvin Glenn Riddick, Winston-Salem, NC (US); Jerry Wayne Marshall, Stokesdale, NC (US)

(72) Inventors: Serban C. Moldoveanu,

Winston-Salem, NC (US); Marvin Glenn Riddick, Winston-Salem, NC (US); Jerry Wayne Marshall,

Stokesdale, NC (US)

(73) Assignee: R.J. Reynolds Tobacco Company,

Winston-Salem, NC (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 20 days.

This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 13/857,677

(22) Filed: Apr. 5, 2013

(65) Prior Publication Data

US 2014/0299136 A1 Oct. 9, 2014

(51) Int. Cl.

 A24B 1/00
 (2006.01)

 A24B 15/28
 (2006.01)

 A24B 15/20
 (2006.01)

 A24B 15/18
 (2006.01)

(52) U.S. Cl.

(58) Field of Classification Search

(56) References Cited

U.S. PATENT DOCUMENTS

1,327,692	A		1/1920	Beinhart	
2,758,603	Α		8/1956	Heljo	
3,132,651	Α		5/1964	Kiefer	
3,240,214	Α		3/1966	Bavley et al.	
3,513,857	Α		5/1970	Silberman	
3,612,065	Α		10/1971	Rosen	
3,636,097	Α		1/1972	Harvey	
3,943,945	Α		3/1976	Rosen	
4,061,488	Α	*	12/1977	Mann	504/117
4,135,521	Α		1/1979	Malan et al.	
4,140,136	Α		2/1979	Geiss et al.	
4,151,848	Α		5/1979	Newton et al.	
4,307,733	Α		12/1981	Teng et al.	
4,308,877	Α		1/1982	Mattina	
4,343,317	Α		8/1982	Bokelman	
4,343,318	Α		8/1982	Brenik et al.	
4,347,859	Α		9/1982	Bokelman et al.	
4,407,307	Α		10/1983	Gaisch et al.	

4,476,881 A	10/1984	Gravely et al.
4,528,993 A	7/1985	Sensabaugh, Jr. et al.
4,556,073 A	12/1985	Gravely et al.
4,557,280 A	12/1985	Gravely et al.
4,566,469 A	1/1986	Semp et al.
4,572,219 A	2/1986	Gaisch et al.
4,660,577 A	4/1987	Sensabaugh et al.
4,709,710 A	12/1987	Gaisch et al.
4,716,911 A	1/1988	Poulose et al.
4,819,668 A *	4/1989	Shelar et al 131/371
4,887,618 A	12/1989	Bernasek et al.
4,941,484 A	7/1990	Clapp et al.
5,099,862 A	3/1992	White et al.
5,343,879 A	9/1994	Teague
5,372,149 A	12/1994	Roth et al.
5,387,416 A	2/1995	White et al.
5,601,097 A	2/1997	De Grandpré et al.
5,676,164 A	10/1997	Martin
5,803,081 A	9/1998	O'Donnell, Jr. et al.
5,869,042 A *	2/1999	Marrone et al 424/93.46
6,202,649 B1	3/2001	Williams
6,564,808 B1	5/2003	Hempfling et al.
6,755,200 B1	6/2004	Hempfling et al.
6,805,134 B2	10/2004	Peele
6,834,654 B2	12/2004	Williams
6,895,974 B2	5/2005	Peele
7,025,066 B2	4/2006	Lawson et al.
7,293,564 B2	11/2007	Perfetti et al.

(Continued) FOREIGN PATENT DOCUMENTS

WO WO 83/01180 4/1983 WO WO 98/05226 2/1998

(Continued) OTHER PUBLICATIONS

Larsson et al "Identification of bacterial and fungal components in tobacco and tobacco smoke", BioMed Central, 2008, [online], Retrieved from the Internet, [Retrieved Dec. 23, 2014], < URL: http://www.tobaccoinduceddiseases.com/content/pdf/1617-9625-4-4.pdf>.*

West et al., "Irrigation Timing—Its influence on the Effects of Salinity and Waterlogging Stresses in Tobacco Plants," *Soil Science*, 1978, vol. 125, No. 6, pp. 367-376.

Ellis et al., "Bacterial Diseases of Plants," *The Ohio State University, Fact Sheet, Agriculture and Natural Resources*, http://ohioline.osu.edu/hyg-fact/3000/.

(Continued)

Primary Examiner — Dennis Cordray (74) Attorney, Agent, or Firm — Womble Carlyle Sandridge & Rice, LLP

(57) ABSTRACT

A method of modifying the content of certain bacteria in uncured tobacco material is provided, the method including contacting an uncured tobacco material with a treatment solution, wherein the treatment solution is selected from the group consisting of: (i) a solution comprising salt, sugar, or a combination thereof; (ii) a solution comprising one or more enzymes; and (iii) a solution comprising one or more probiotics, wherein said contacting provides a treated tobacco material having a reduced total bacterial content following harvest. In certain embodiments, the treated tobacco material is subsequently cured, and can optionally be fermented. Smoking articles and smokeless tobacco products including such treated tobacco materials are also provided.

32 Claims, 2 Drawing Sheets

(56) References Cited

U.S. PATENT DOCUMENTS

7,549,425	B2	6/2009	Koga et al.
7,549,426	B2	6/2009	Koga et al.
7,556,046	B2	7/2009	Koga et al.
8,353,300	B2	1/2013	Li et al.
2003/0056801	A1	3/2003	Krauss et al.
2005/0072047	A1	4/2005	Conkling et al.
2006/0037623	A1	2/2006	Lawrence, Jr.
2006/0196516	A1	9/2006	Cui et al.
2008/0152684	A1*	6/2008	Tzeng et al 424/405
2008/0245377	A1	10/2008	Marshall et al.
2010/0116281	A1	5/2010	Marshall et al.
2012/0125354	A1	5/2012	Byrd et al.
2012/0234334	A1	9/2012	Chen et al.
2012/0279510	A1	11/2012	Marshall et al.
2013/0269719	A1*	10/2013	Marshall et al 131/290
2014/0020694	A1*	1/2014	Moldoveanu et al 131/280

FOREIGN PATENT DOCUMENTS

WO	WO 98/58555	12/1998
WO	WO 00/02464	1/2000
WO	WO 02/13636	2/2002
WO	WO 03/094639	11/2003

OTHER PUBLICATIONS

Heyser et al., "Osmotic Adjustment of Cultured Tobacco Cells (*Nicotiana tabacum* var. Samsum) Grown on Sodium Chloride," *Plant Physiol.*, 1981, pp. 720-727, vol. 67.

Huang et al., "Bacterial Diversities on Unaged and Aging Flu-Cured Tobacco Leaves Estimated by 16S rRNA Sequence Analysis," *Appl. Microbiol. Biotechnol.*, 2010, pp. 553-562, vol. 88, No. 2.


Larsson el al., "Identification of Bacterial and Fungal Components in Tobacco and Tobacco Smoke," *Tobacco Induced Diseases*, 2008, pp. 1-8, vol. 4, No. 4. http://www.tobaccoinduceddiseases.com/content/4/1/4.

Larsson et al., "Microbiological Components in Mainstream and Sidestream Cigarette Smoke," *Tobacco Induced Diseases*, 2012, pp. 1-5, vol. 10, No. 13. http://www.tobaccoinduceddiseases.com/content/10/1/13.

Mitchell, "Changes in the Microflora of Tobacco Leaves During Field Growth in England," *Paper for Presentation: Coresta Meeting, Cesme*, Turkey, Oct. 1989, http://legacy.library.ucsf.edu/tid/num81a99/pdf.

Müller et al. "Isolation and Characterization of Cell Lines of *Nicotiana tabacum* Nitrate Reductase," *Molec. Gen. Genet.* 161, pp. 67-76 (1978).

^{*} cited by examiner






FIG. 2

MODIFICATION OF BACTERIAL PROFILE OF TOBACCO

FIELD OF THE INVENTION

The present invention relates to plants and modifications to the method of growing, harvesting, and/or treating plants (e.g., tobacco). Particularly, the present invention relates to products made or derived from tobacco, or that otherwise incorporate tobacco, and are intended for human consump-

BACKGROUND OF THE INVENTION

Popular smoking articles, such as cigarettes, have a sub- 15 stantially cylindrical rod shaped structure and include a charge, roll or column of smokable material such as shredded tobacco (e.g., in cut filler form) surrounded by a paper wrapper thereby forming a so-called "tobacco rod." Normally, a cigarette has a cylindrical filter element aligned in an end-to- 20 end relationship with the tobacco rod. Typically, a filter element comprises plasticized cellulose acetate tow circumscribed by a paper material known as "plug wrap." Certain cigarettes incorporate a filter element having multiple segments, and one of those segments can comprise activated 25 charcoal particles. Typically, the filter element is attached to one end of the tobacco rod using a circumscribing wrapping material known as "tipping paper." It also has become desirable to perforate the tipping material and plug wrap, in order to provide dilution of drawn mainstream smoke with ambient 30 air. A cigarette is employed by a smoker by lighting one end thereof and burning the tobacco rod. The smoker then receives mainstream smoke into his/her mouth by drawing on the opposite end (e.g., the filter end) of the cigarette.

The tobacco used for cigarette manufacture is typically 35 used in blended form. For example, certain popular tobacco blends, commonly referred to as "American blends," comprise mixtures of flue-cured tobacco, burley tobacco and Oriental tobacco, and in many cases, certain processed tobaccos, such as reconstituted tobacco and processed tobacco stems. 40 The precise amount of each type of tobacco within a tobacco blend used for the manufacture of a particular cigarette brand varies from brand to brand. However, for many tobacco blends, flue-cured tobacco makes up a relatively large proportion of the blend, while Oriental tobacco makes up a 45 relatively small proportion of the blend. See, for example, Tobacco Encyclopedia, Voges (Ed.) p. 44-45 (1984), Browne, The Design of Cigarettes, 3rd Ed., p. 43 (1990) and Tobacco Production, Chemistry and Technology, Davis et al. (Eds.) p. 346 (1999).

Tobacco also may be enjoyed in a so-called "smokeless" form. Particularly popular smokeless tobacco products are employed by inserting some form of processed tobacco or tobacco-containing formulation into the mouth of the user. Various types of smokeless tobacco products are known. See 55 for example, the types of smokeless tobacco formulations, ingredients, and processing methodologies set forth in U.S. Pat. No. 1,376,586 to Schwartz; U.S. Pat. No. 3,696,917 to Levi; U.S. Pat. No. 4,513,756 to Pittman et al.; U.S. Pat. No. 4,528,993 to Sensabaugh, Jr. et al.; U.S. Pat. No. 4,624,269 to 60 Story et al.; U.S. Pat. No. 4,991,599 to Tibbetts; U.S. Pat. No. 4,987,907 to Townsend; U.S. Pat. No. 5,092,352 to Sprinkle, III et al.; U.S. Pat. No. 5,387,416 to White et al.; U.S. Pat. No. 6,668,839 to Williams; U.S. Pat. No. 6,834,654 to Williams; U.S. Pat. No. 6,953,040 to Atchley et al.; U.S. Pat. No. 7,032, 65 601 to Atchley et al.; and U.S. Pat. No. 7,694,686 to Atchley et al.; US Pat. Pub. Nos. 2004/0020503 to Williams; 2005/

2

0115580 to Quinter et al.; 2006/0191548 to Strickland et al.; 2007/0062549 to Holton, Jr. et al.; 2007/0186941 to Holton, Jr. et al.; 2007/0186941 to Holton, Jr. et al.; 2008/0029110 to Dube et al.; 2008/0029116 to Robinson et al.; 2008/0173317 to Robinson et al.; 2008/0196730 to Engstrom et al.; 2008/0209586 to Neilsen et al.; 2008/0305216 to Crawford et al.; 2009/0065013 to Essen et al.; 2009/0293889 to Kumar et al.; 2010/0291245 to Gao et al; and 2011/0139164 to Mua et al.; PCT WO 04/095959 to Arnarp et al. and WO 2010/132444 to Atchley; each of which is incorporated herein by reference.

One type of smokeless tobacco product is referred to as "snuff." Representative types of moist snuff products, commonly referred to as "snus," have been manufactured in Europe, particularly in Sweden, by or through companies such as Swedish Match AB, Fiedler & Lundgren AB, Gustavus AB, Skandinavisk Tobakskompagni A/S, and Rocker Production AB. Snus products available in the U.S.A. have been marketed under the tradenames Camel Snus Frost, Camel Snus Original and Camel Snus Spice by R. J. Reynolds Tobacco Company. See also, for example, Bryzgalov et al., 1N1800 Life Cycle Assessment, Comparative Life Cycle Assessment of General Loose and Portion Snus (2005). In addition, certain quality standards associated with snus manufacture have been assembled as a so-called GothiaTek standard. Representative smokeless tobacco products also have been marketed under the tradenames Oliver Twist by House of Oliver Twist A/S; Copenhagen, Skoal, SkoalDry, Rooster, Red Seal, Husky, and Revel by U.S. Smokeless Tobacco Co.; "taboka" by Philip Morris USA; Levi Garrett, Peachy, Taylor's Pride, Kodiak, Hawken Wintergreen, Grizzly, Dental, Kentucky King, and Mammoth Cave by Conwood Company, LLC; and Camel Orbs, Camel Sticks, and Camel Strips by R. J. Reynolds Tobacco Company.

Through the years, various treatment methods and additives have been proposed for altering the overall character or nature of tobacco materials utilized in tobacco products. For example, additives or treatment processes have been utilized in order to alter the chemistry or sensory properties of the tobacco material, or in the case of smokable tobacco materials, to alter the chemistry or sensory properties of mainstream smoke generated by smoking articles including the tobacco material. Various types of enzymes, bacteria, and microorganisms (e.g., fungi and yeast) have been employed in conjunction with tobacco for the purpose of altering the chemical makeup of the tobacco, e.g., by reducing the content of certain chemical compounds. See, for example, U.S. Pat. No. 3,132, 651 to Keifer; U.S. Pat. No. 3,513,857 to Silberman; U.S. Pat. No. 3,240,214 to Bayley; U.S. Pat. No. 3,636,097 to Harvey; U.S. Pat. No. 3,612,065 to Rosen; U.S. Pat. No. 3,943,945 to Rosen; U.S. Pat. No. 4,135,521 to Malan; U.S. Pat. No. 4,140, 136 to Geiss et al.; U.S. Pat. No. 4,151,848 to Newton et al.; U.S. Pat. No. 4,307,733 to Teng; U.S. Pat. No. 4,308,877 to Mattina et al.; U.S. Pat. No. 4,407,307 to Gaisch; U.S. Pat. No. 4,476,881 to Gravely et al.; U.S. Pat. No. 4,556,073 to Gravely et al.; U.S. Pat. No. 4,557,280 to Gravely et al.; U.S. Pat. No. 4,566,469 to Semp et al.; U.S. Pat. No. 4,572,219 to Gaisch; U.S. Pat. No. 4,709,710 to Gaisch; U.S. Pat. No. 4,716,911 to Poulose; U.S. Pat. No. 4,887,618 to Bernasek; U.S. Pat. No. 4,941,484 to Clapp; U.S. Pat. No. 5,099,862 to White; U.S. Pat. No. 5,343,879 to Teague; U.S. Pat. No. 5,372,149 to Roth et al.; U.S. Pat. No. 5,601,097 to DeGranpreet; U.S. Pat. No. 7,549,425 to Koga et al.; U.S. Pat. No. 7,549,426 to Koga et al.; and U.S. Pat. No. 7,556,046 to Koga et al.; Int. Appl. Publ. No. WO 2000/02464 to Kierulff; and EP Appl. No. 1094724 to Kierulff, which are all incorporated herein by reference.

It would be desirable in the art to provide further methods for altering the character and nature of a plant such as a tobacco plant, as well as tobacco compositions and formulations useful in smoking articles or smokeless tobacco prod-

SUMMARY OF THE INVENTION

The present disclosure provides a method of treating a plant or a portion thereof to modify (e.g., increase and/or 10 decrease) the amount of certain bacteria present therein. Particularly, the disclosed methods can be applied to tobacco plants and materials and can, in some embodiments, result in a decrease in total bacterial content associated with the tobacco plant or material and/or an increase in Lactobacillus 15 bacterial content associated with the tobacco plant or mate-

In one aspect of the invention is provided a method of modifying the bacterial content of a tobacco material, comprising contacting an unharvested tobacco material up to 20 about 24 hours before harvest with a treatment solution, wherein the treatment solution is selected from the group consisting of: (i) a solution comprising salt, sugar, or a combination thereof; (ii) a solution comprising one or more enzymes; and (iii) a solution comprising one or more probi- 25 otics, wherein said contacting provides a treated tobacco material having a reduced total bacterial content following harvest.

In certain embodiments, the treatment solution can comprise NaCl. In some embodiments, the treatment solution has 30 a concentration of salt, sugar, or a combination thereof of between about 1 and about 4 percent by weight. The treatment solution can, in some embodiments, comprise Lactobacillus bacteria. For example, the treatment solution may comprise Lactobacillus helveticus. Where the treatment solution com- 35 prises probiotic bacteria, the treatment solution may, for example, have a concentration of probiotic bacteria of between about 1×10⁵ colony forming units/mL and about 1×10^{10} colony forming units/mL. Where the treatment solution comprises an enzyme, the treatment solution may, for 40 invention, reference is made to the appended drawings, which example, have a concentration of enzyme of between about 10 AU and about 50,000 AU per plant.

In one embodiment, the method further comprises curing the treated tobacco material to give a treated, cured tobacco material. In certain embodiments, the tobacco-specific nitro- 45 samine (TSNA) content of the treated, cured tobacco material is reduced relative to an untreated, cured tobacco material. In another aspect of the invention is provided a method of modifying the bacterial content of a tobacco material, comprising: contacting an unharvested tobacco material up to about 24 50 hours before harvest with a salt solution comprising NaCl in a concentration of about 0.5% to about 15% by weight of the treatment solution, wherein said contacting provides a treated tobacco material having a reduced total bacterial content following harvest; harvesting the treated tobacco material; 55 and curing the harvested, treated tobacco material to give a treated, cured tobacco material.

The unharvested tobacco material can be, for example, selected from the group consisting of a tobacco seed, a tobacco seedling, an immature live plant, a mature live plant, 60 or a portion thereof. In certain embodiments, the total bacterial content of the treated tobacco material is reduced by at least about 50% in number following harvest and in certain embodiments, the total bacterial content of the treated tobacco material is reduced by at least about 80% in number 65 following harvest. In some embodiments, the total bacterial content of the tobacco material comprises Gram-negative

bacteria and wherein the Gram-negative bacterial content of the treated tobacco material is reduced by at least about 50% in number following harvest. In some embodiments, the total bacterial content of the tobacco material comprises bacteria of the Lactobacillus genus, and wherein the Lactobacillus bacterial content of the treated tobacco material is increased following harvest.

One or more additional components can be added to the treatment solution. For example, the treatment solution can further comprise one or more surfactants. Various additional steps can be included in the methods provided herein. In some embodiments, the method can further comprise subjecting the treated, cured tobacco material to fermentation, wherein the fermentation is completed in less time than that required for fermentation of untreated, cured tobacco material. In some embodiments, the method can further comprise processing the treated, cured tobacco material to provide a processed tobacco material in a form suitable for incorporation in a tobacco product; and incorporating the processed tobacco material into a smokeless tobacco product or a smoking article. The processed tobacco material can be, for example, in the form of cut filler and/or a tobacco blend. In one embodiment, the method comprises contacting an unharvested tobacco material with a solution containing salt to give a treated tobacco material; harvesting and curing the treated tobacco material; subjecting the cured tobacco material to fermentation; and incorporating the fermented tobacco material into a smokeless tobacco product.

Tobacco products, in the form of smoking articles (e.g., cigarettes) or smokeless tobacco products, prepared according to the methods described herein, are also provided. In some embodiments, a smoking article produced according to the methods provided herein, upon smoking, is characterized by a TSNA content of mainstream smoke that is reduced relative to an untreated control smoking article.

BRIEF DESCRIPTION OF THE DRAWINGS

In order to provide an understanding of embodiments of the are not necessarily drawn to scale, and in which reference numerals refer to components of exemplary embodiments of the invention. The drawings are exemplary only, and should not be construed as limiting the invention.

FIG. 1 is an exploded perspective view of a smoking article having the form of a cigarette, showing the smokable material, the wrapping material components, and the filter element of the cigarette; and

FIG. 2 is a cross-sectional view of a smokeless tobacco product embodiment, taken across the width of the product, showing an outer pouch filled with a smokeless tobacco composition of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention now will be described more fully hereinafter. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. As used in this specification and the claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Reference to "dry weight percent" or "dry weight basis" refers to weight on the basis of dry ingredients (i.e., all ingredients except water).

The invention provides plants, plant components, and plant materials having modified levels of certain bacteria. In some embodiments, these plants, plant components, and plant materials having modified bacteria levels are subjected to curing and can exhibit modified levels of various compounds (e.g., tobacco-specific nitrosamines, TSNAs) post-curing. In one exemplary aspect, the invention provides tobacco plants, plant components, or tobacco materials having modified levels of certain bacteria and/or various compounds, tobacco products incorporating tobacco material derived from such tobacco, and methods for preparing a tobacco having modified levels of certain bacteria and/or compounds and for incorporating tobacco material derived from this tobacco within tobacco products.

The method of modifying levels of certain bacteria within 15 tobacco materials generally comprises treating tobacco (in various forms, e.g., in unharvested or harvested form) by contacting the tobacco with one or more of: a salt and/or sugar solution; a probiotic solution; and/or an enzyme solution (collectively referred to herein as "treatment solutions"). It is 20 noted that although the discussion provided herein focuses in large part on treatment of tobacco, a variety of other plants (including fruits, vegetables, flowers, and components thereof) can be treated according to the methods provided herein to afford plants, plant components, and materials and 25 products produced therefrom having modified levels of certain compounds (e.g., bacteria) therein.

The tobacco can be treated in various stages of the plant life cycle, but typically is treated prior to or during the early phase of curing of the tobacco plant or plant component (i.e., the 30 tobacco plant or plant component is "uncured or partially cured tobacco," which encompasses treatment prior to harvest and through the yellowing/browning phases of curing with the treatment solution). The yellowing/browning phase occurs during curing and describes a point at which the 35 tobacco is harvested but has not undergone complete curing.

In certain preferred embodiments, the tobacco is treated prior to curing, i.e., in "green" form. By "green" in certain embodiments is meant tobacco having a form such that cells within the plant or plant component have not experienced 40 significant or substantial cell death, and cellular respiration is capable of occurring to some degree. Although a tobacco material in "green" form can be in harvested or unharvested form, in certain embodiments, the tobacco material undergoing treatment as described herein is unharvested.

Accordingly, by "tobacco," "tobacco plant," or "tobacco plant components" is meant tobacco at various stages of the tobacco plant life cycle. For example, the tobacco plant component that is treated according to the present disclosure can be a tobacco seed, tobacco seedling, unharvested tobacco 50 plant (at varying stages of maturity), harvested plant, or a portion of any of the above, which are all considered to be stages of the tobacco plant as described in further detail herein. In certain embodiments, the tobacco is treated prior to being dried (i.e., before harvest or just after harvest). In some 55 embodiments, the tobacco is treated in a form wherein it is considered to be "alive." In certain embodiments, the tobacco is field-treated, meaning that the treatment is conducted on at least a portion of tobacco plants in unharvested form. In some embodiments, an unharvested tobacco plant that can be 60 treated as described herein can be further described as growing in the field, having its roots in the ground, and continuing to go through the normal biological activity of a living organism.

In certain embodiments, the treatment can be performed 65 within a specific time range prior to harvest. For example, in some embodiments, it may be beneficial to treat the tobacco

6

less than about a week before harvest, including less than about 2 days before harvest or less than about 1 day before harvest. In certain embodiments, it may be advantageous to treat the tobacco a given number of hours before harvest, e.g., between about 1 and about 24 hours before harvest, between about 2 and about 12 hours before harvest, or between about 3 and about 10 hours before harvest. For example, the tobacco may be treated less than about 24 hours before harvest, less than about 15 hours before harvest, less than about 12 hours before harvest, less than about 10 hours before harvest, less than about 8 hours before harvest, or less than about 6 hours before harvest. In one embodiment, the tobacco is treated about 5 hours before harvest. Field treatment is particularly beneficial within a limited period of time before harvest, e.g., to avoid the diluting effects of rain and the possibly damaging effects of drying and UV radiation. It is noted that, in some embodiments, treatment may be conducted on an intact tobacco plant, whereas in other embodiments, treatment may be conducted on a plant having a portion removed therefrom (e.g., where the flower has been removed from the plant or where a portion of the leaves have bee removed from the plant prior to treatment).

As noted above, the treatment solution can generally comprise one or more of: a salt and/or sugar solution; a probiotic solution; and/or an enzyme solution. Each of these types of treatment solutions will be described in greater detail herein. It is also to be understood that mixtures of such solutions can also be used in certain embodiments of the methods described herein (e.g., a probiotic-containing salt and/or sugar solution, an enzyme-containing salt and/or sugar solution, or a solution containing both an enzyme and a probiotic). The treatment solutions are generally described herein as being in liquid (solution) form. Although they are described as treatment "solutions," it is noted that some percentage of the solids can, in some embodiments, be incompletely dissolved (e.g., such that the "treatment solution" can be in solution, dispersion, or suspension form). The liquid with which the salt, sugar, enzyme, and/or probiotic is mixed can vary, but generally, the liquid will comprise water. Although in preferred embodiments, the solutions are aqueous solutions (i.e., comprising water), various other solvents (e.g., polar organic solvents such as methanol, ethanol, and propanol) can be used instead or in addition to the water. The concentration and amount of the salt, sugar, probiotic, or enzyme used can vary. Generally, the amount of the salt, sugar, probiotic, or enzyme is an amount sufficient to change the amount of one or more types of bacteria in the tobacco material to which it is applied. In other embodiments, application of the salt, sugar, probiotic, and/or enzyme can be performed with the salt, sugar, probiotic, and/or enzyme in a dry (e.g., freeze-dried) form. For example, methods analogous to those used in ensiling forage or dry salting can, in some embodiments, be used herein. See, for example, Stevens H. R., On Ensilage of Green Forage Crops in Silos (1881), which is incorporated herein by refer-

In embodiments wherein the treatment solution comprises a salt and/or sugar solution, the specific makeup of the solution can vary. In certain embodiments, the treatment solution may be such that it is hypertonic with respect to the plant or portion thereof subjected to treatment. A hypertonic solution is generally understood to be a solution with a high concentration of solute as compared with another solution, from which it is separated, e.g., by a semi-permeable membrane. Due to the higher concentration of solute on the hypertonic solution side of the membrane, fluid will generally flow across the membrane and into the hypertonic solution until an isotonic state is reached (wherein the solute concentrations on

the two sides of the membrane are identical). In the context of the present application, a hypertonic solution is understood to be a solution wherein the solute or solutes in the solution are at a concentration that is higher than the concentration of that solute or solutes in the plant to be treated.

In certain embodiment, the treatment solution is a salt solution. Salt solution treatment of various types of plants is known, for example, as described in U.S. Pat. No. 6,755,200 to Hempffing et al. and US Pat. Appl. Publ. Nos. 2008/ 0202538 to Li et al. and 2012/0279510 to Marshall et al., 10 which are all incorporated herein by reference. Any salt can be used for this purpose, although food-grade salts are especially preferred. Exemplary salts include, but are not limited to, sodium chloride (NaCl), calcium chloride (CaCl₂), magnesium chloride (MgCl₂), potassium chloride (KCl), and 15 combinations thereof. In certain preferred embodiments, the treatment solution is a NaCl solution. In some embodiments, the salt solution is not a bicarbonate or carbonate anioncontaining solution. The salt can be iodized or non-iodized preferably is non-iodized. The salt can be, for example, kosher salt, sea salt, or pickling salt. The particle size and shape of the salt can vary (e.g., the salt can be granulated, flaked, or powdered), so long as at least a portion of the salt particles are capable of being dissolved, e.g., in water, to form 25 a solution.

In certain embodiments, the solute comprises sugar. Any sugar, including food-grade sugars, can be used for this purpose, e.g., including but not limited to, sucrose, glucose, fructose, galactose, maltose, and lactose, rhamnose, xylose, 30 and combinations thereof. The form of sugar used according to the present disclosure can be, for example, powdered, crystalline, or syrup form, so long as at least a portion of the sugar is capable of being dissolved, e.g., in water, to form a hypotonic solution. In some embodiments, a solution com- 35 prising both salt and sugar can be used according to the method disclosed herein.

In embodiments wherein the treatment solution comprises a probiotic-containing solution, the solution can be, for example, as described in U.S. patent application Ser. No. 40 13/444,272 to Marshall et al., filed on Apr. 11, 2012, which is incorporated herein by reference. Briefly, probiotic treatment comprises treatment with one or more "probiotics" or "probiotic microorganisms" which are intended to encompass all live microorganisms that may be classified as probiotics by 45 various sources. For example, the Food and Agriculture Organization of the United Nations (FAO) defines probiotics as "live microorganisms, which, when administered in adequate amounts, confer a health benefit on the host." In some reports, such health benefits can include, but are not limited to: colo- 50 nization of the intestinal, respiratory, and/or urogenital tracts, cholesterol metabolism, lactose metabolism, absorption of calcium, synthesis of vitamins, reduction of yeast and vaginal infections, reduction of digestive problems (e.g., constipation and diarrheal diseases), production of natural antibiotics, lac- 55 tic acid, enzymes, hydrogen peroxide, inhibition of pathogenic microorganisms by production of antibiotic-like substances; and a decrease in pH. Although the traditional definition of "probiotic" relates to human and animal digestive organisms, this term has been applied in other contexts, 60 such as in the field of agriculture. Exemplary probiotics include, but are not limited to, bifidobacterium adolescentis, bifidobacterium animalis, bifidobacterium bifidum, bifidobacterium breve, bifidobacterium infantis, bifidobacterium bifidobacterium longum, bifidobacterium 65 pseudocatenulatum, bifidobacterium pseudolongum, bifidobacterium sp., bifidobacterium thermophilum, lactobacillus

acidophilus, lactobacillus alimentarius, lactobacillus amylovorus lactobacillus bulgaricus, lactobacillus bifidus, lactobacillus brevis, lactobacillus casei, lactobacillus caucasicus, lactobacillus crispatus, lactobacillus curvatus, lactobacillus delbruckii, lactobacillus fermentum, lactobacillus gallinarum, lactobacillus gas seri, lactobacillus helveticus, lactobacillus johnsonii, lactobacillus lactis, lactobacillus leichmannii, lactobacillus paracasei, lactobacillus plantarum, lactobacillus reuteri, lactobacillus rhamnosus, lactobacillus salivarius, lactobacillus sp., lactobacillus sporogenes, lactococcus lactis, streptococcus cermoris, streptococcus faceium, streptococcus infantis, streptococcus thermophilus, enterococcus faceium, pediococcus acidilactici, staphylococcus thermophilus, staphylococcus carnosus, staphylococcus xylosus, saccharomyces boulardii, saccharomyces cerevisiae, saccharomyces boulardii, bacillus cereus var toyo, bacillus subtilis, bacillus coagulans, and bacillus lichenifor-

In embodiments wherein the treatment solution comprises (i.e., having a small amount of iodine added thereto), but 20 an enzyme-containing solution, the solution can be, for example, as described in U.S. patent application Ser. No. 13/553,222 to Moldoveanu et al., filed Jul. 19, 2012, which is incorporated herein by reference. Briefly, enzymatic treatment comprises treatment with one or more enzymes, which as used herein, refers to any globular protein of varying size and structure. Generally, enzymes that are useful according to the invention function in some way to catalyze one or more chemical reactions within the plant material (e.g., by increasing the rate thereof). Any type of enzyme or combination of enzyme types can be employed according to the present invention; for example, hydrolases (which catalyze hydrolysis of chemical bonds), isomerases (which catalyze isomerizations within a molecule), ligases (which function to link two or more molecules), lyases (which cleave chemical bonds by mechanisms other than hydrolysis and oxidation), oxidoreductases (which catalyze oxidation/reduction reactions), and transferases (which transfer various moieties, e.g., functional groups). The origin of the enzymes can vary and the enzymes can be obtained, for example, from microbial sources (e.g., bacterial sources or fungal sources), plant sources, animal sources, and/or can be synthetically produced. Exemplary enzymes include, but are not limited to, amylases (e.g., α -amylase, β -amylase, γ -amylase, or a combination thereof) and/or proteases (e.g., serine proteases, threonine proteases, cysteine proteases, asparatate proteases, metalloproteases, and glutamic acid proteases including protease bacillus licheniformis, protease bacillus sp., protease Aspergillus oryzae, protease bacillus amyloliquefaciens, protease bacillus, and protease Streptomyces griseus). In certain embodiments, the one or more enzymes comprise asparaginase (e.g., PreventASeTM, DSM Food Specialties, Heerlen, NL and Acrylaway®, Novozymes, A/S, Bagsvaerd, DK). In certain embodiments, the one or more enzymes comprise a polyphenol oxidase (PPO). In some embodiments, the one or more enzymes comprise an oxidase such as a monophenol oxidase enzyme (tyrosinase) or an o-diphenol oxygen oxidoreductase enzyme (catechol oxidase). Another exemplary oxidase is laccase.

> The solute of the treatment solution (i.e., the salt(s), sugar(s), probiotics, enzymes, or combination thereof) can be present in varying concentrations. Generally, a somewhat dilute solution is used according to the methods provided herein, although the concentration can be any concentration sufficient to elicit the desired effect in the treated tobacco plant.

> For example, in some embodiments, salt, sugar, or a combination thereof is present in a concentration of about 0.5% to

about 15% by weight of the treatment solution, about 0.5% to about 10%, or about 1% to about 5% by weight of the treatment solution (e.g., about 1.5%, about 2%, about 2.5%, or about 3% by weight of the treatment solution).

In some embodiments, the treatment solution comprises a 5 probiotic in an amount of between about 1×10⁵ colony forming units (CFU)/mL and about 1×10¹⁰ CFU/mL (e.g., about 2×10⁶ CFU/mL) CFU provides a measurement of viable (living) cells in the probiotic sample.

In some embodiments, the treatment solution comprises an 10 enzyme in an amount of between about 10 and about 50,000 active units (AU) per plant. For example, exemplary amounts of the enzyme can be between about 100 and about 10,000 AU per plant, e.g., between about 500 and about 5,000 AU per plant (typical AU level for a commercial product Preven- 15 tASeTM L (from DSM) is 2,600 AU/mL for the preparate of asparaginase). For dry tobacco (~12% moisture), a range between 20 and 100 AU/g can be used. In embodiments wherein the enzyme comprises commercial polyphenol oxidase (PPO), between about 100 and about 10,000 AU per 20 plant, e.g., between about 1,000 and about 5,000 AU per plant can be used (typical AU level for a commercial product (from Worthington) is 1,000 AU/mL for the preparate).

In certain embodiments, other components can be applied to the plant with the treatment solution. Such components can 25 be added within the same formulation (e.g., within the same solution, dispersion, suspension) or can be applied to the tobacco in a separate formulation. For example, in some embodiments, one or more surfactants and/or detergents are applied to the tobacco with the sugar, salt, enzyme, and/or 30 probiotic. The surfactants can be, for example, non-ionic surfactants. Various surfactants can be used, including, but not limited to, polysorbate surfactants, such as polysorbate 20 (Tween-20®) and polysorbate 80 (Tween-80®) and poly(ethylene glycol)-based surfactants, such as Triton™ X Series 35 surfactants. Other reagents for helping the treatment solution coat the tobacco effectively can include various sugars, plant extracts (e.g., yucca extracts, seaweed extracts), and derivatives thereof. Certain enzymes and probiotics are active only within a particular pH range; therefore, use of pH adjusters, 40 acids, bases, and/or buffers may be beneficial in the application of certain treatment solutions. In some embodiments, the treatment solution may contain one or more amino acids (e.g., lysine, glycine, histidine, alanine, methionine, glutamic acid, aspartic acid, proline, phenylalanine, valine, and arginine), 45 compositions incorporating cations (e.g., di- and/or trivalent cations), certain non-reducing saccharides, certain reducing agents, phenolic compounds (e.g., compounds having at least one phenolic functionality), certain compounds having at least one free thiol group or functionality, oxidizing agents 50 (e.g., hydrogen peroxide or ozone), oxidation catalysts (e.g., titanium dioxide), natural plant extracts (e.g., rosemary extract), and combinations thereof. The amount of the one or more other components that can optionally be added to the certain embodiments, the treatment solution may comprise up to about 25% by weight of the treatment solution, e.g., between about 1 and about 20% by weight.

As noted above, the treatment can comprise treating the tobacco material (e.g., green tobacco plant material) with one 60 or more of the types of treatment solutions described herein. Such treatments can, in some embodiments, comprise treating the tobacco with two or more different types of treatment solutions sequentially (e.g., in close succession or at significantly different time points) or simultaneously (e.g., by sepa- 65 rately applying two or more different solutions to the tobacco or by mixing the solutions to provide a single treatment solu10

tion comprising two or more different solutes and applying the single treatment solution to the tobacco). Tobacco can be treated with a treatment solution (i.e., a salt and/or sugar solution; a probiotic solution; and/or an enzyme solution) once or can be treated multiple times. In some embodiments, two treatment solutions, which may be the same or different, can be provided in separate formulations and applied at different points of the tobacco plant life cycle (e.g., with one applied to growing plants in the field and one applied following harvest or with one applied to seeds and one applied to growing plants in the field).

Treatment of tobacco with a treatment solution according to the methods provided herein can have varying effects on the resulting treated tobacco. It is noted that the specific results obtained may be related, at least in part, to the specific type of salt(s), sugar(s), enzyme(s), and/or probiotic(s) that are used in the treatment.

For example, in certain embodiments, tobacco treated with a salt and/or sugar solution; a probiotic solution; and/or an enzyme solution can exhibit modified levels of certain bacteria associated therewith. It is known that tobacco plants naturally have various levels of bacteria associated therewith. See, for example, Larsson L. et al., Tobacco Induced Diseases, 4:4 (2008) and Huang J. et al., Appl. Microbiol. Biotechnol. 88(2): 553 (2010), which are incorporated herein by refer-

"Bacteria" is generally understood to refer to a genus of prokaryotic microorganisms scientifically classified as such. Most bacteria can be classified as Gram-positive (classified principally in the phylum "Actinobacteria") or Gram-negative (classified principally in the phylum "Proteobacteria"). "Gram-negative" as referred to herein relates to bacteria bounded by a cytoplasmic membrane as well as an outer cell membrane, containing only a thin layer of peptidoglycan between the two membranes, which is unable to retain crystal violet stain in a Gram staining technique (whereas Grampositive bacteria are bounded by only a single unit lipid membrane and contain a thick layer (20-80 nm) of peptidoglycan, which retains the stain). Exemplary Gram-negative bacteria include, but are not limited to, proteobacteria (e.g., from the genera Enterobacteriaceae (including Escherichia, Salmonella, Shigella, Serratia, Pantoea, Proteus, and Klebsiella), Pseudomonaceae (including Pseudomonas and Rhizobacter), Moraxellacae (e.g., Moraxella and Acinetobacter), Helicobacteracae (e.g., Helicobacter), Xanthomonadacae (e.g., Stenotrophomonas and Xanthomonas), Bdellovibrionacaea (e.g., Bdellovibrio), Burkholderiaceae (e.g., Burkholderia), Legionellaceae (e.g., Legionella), Rhizobiaceae (e.g., Agrobacterium); Acetobacteraceae (e.g., acetic acid bacteria), Spirillaceae (e.g., Spirillum), and Campylobacteraceae (e.g., Campylobacter)). In some embodiments, certain bacteria associated with tobacco plants are anaerobic microorganisms.

Enteric bacteria are gram-negative, anaerobic bacteria of plant with the treatment solution can vary. For example, in 55 the family Enterobactericeae that are commonly found in the gut of animals, including humans. Over 40 genera have been identified in this family, including Salmonella, Proteus, Serratia, Enterobacter, Citrobacter, Pseudomonas, and Klebsiella. Other bacterial types typically found in the gut of animals can also be considered enteric bacteria, e.g., bacteria belong to the genera Bacteroides, Clostridium, Fusobacterium, Eubacterium, Ruminococcus, Peptidococcus, Peptostreptococcus, Eschericia, and Bifidobacterium. Various tests to quantify enteric bacteria may also quantify certain other gram negative bacteria in addition to Enterobactericeae (e.g., Salmonella and Eschericia). Although some of these bacteria can live in the gut without health problems, some can

are opportunistic pathogens and/or cause signs of infection, and the presence of such bacteria is thus often advantageously minimized.

Lactobacillus is a specific large genus of gram-positive rod-shaped bacteria that produce lactic acid. Many bacteria in 5 this genus are beneficial (and thus commonly used in probiotic preparations).

In some embodiments, the treatment described herein results in a treated tobacco plant material having a modified total bacteria count, a modified enteric bacteria count, a modified gram-negative bacteria count, and/or a modified *Lactobacillus* count. Although not intended to be limiting, it is believed that, in some embodiments, sugar and/or salt solutions can modify the bacteria count by creating a hypertonic solution with respect to the tobacco material and that probiotics and/or enzymes can modify the bacteria count by providing a competitive bacterial load per unit area associated with the tobacco material.

In certain embodiments, treatment as described herein provides a treated tobacco plant material with a modified total 20 bacteria count and, specifically, may provide an overall reduction in total bacteria count. A total bacteria count can be conducted using any method known in the art, e.g., by diluting a sample and plating the diluted sample(s) on a growth medium (e.g., plate count agar, PCA). The plate is then incu- 25 bated, and each bacterium present in the sample is expected to grow into an individual colony on the plate. The resulting colonies can be viewed (e.g., under a microscope) and counted to provide a total bacterial count in colony forming units/gram (CFU/g). Other methods include, but are not lim- 30 ited to, using counting chambers, using membrane filters that are capable of retaining bacteria, photometry and/or spectroscopy (e.g., turbidimetric analysis). The reduction in the total bacteria count following treatment with one or more of: a salt and/or sugar solution; a probiotic solution; and/or an enzyme 35 solution can be, for example, a reduction of greater than about 80%, greater than about 85%, greater than about 90%, greater than about 92%, greater than about 95%, or greater than about 96%, based on total bacterial counts (obtained, e.g., by taking colony forming units/gram of a treated tobacco sample, divid-40 ing it by colony forming units/gram of an untreated tobacco sample, subtracting the resulting number from 1, and multiplying by 100).

It is understood that some percentage of the total bacteria present on the tobacco plant material prior to treatment will 45 comprise gram negative bacteria. Therefore, it follows that, following treatment, the tobacco plant material may generally exhibit a modified gram-negative bacteria count and, specifically, may exhibit an overall reduction in gram-negative bacteria count. In some embodiments, the decrease in gramnegative bacteria count as described above before and after treatment using a method specific for gram-negative (as opposed to gram-positive) bacteria. Such a method can, in some embodiments, comprise gram staining, observing the bacteria under 55 a microscope, rapid microbial identification systems, and/or polymerase chain reaction (PCR) protocols.

In certain embodiments, treatment as described herein provides a tobacco plant material with a modified enteric bacteria count and, specifically, may provide a plant material with an 60 overall reduction in enteric bacteria count. Enteric bacteria count can be quantified, for example, by the total bacterial count method described above, wherein the bacteria are grown on a selective medium rather than a general bacterial growth medium (e.g., a violet red bile agar (VRBA) plate 65 rather than a plate count agar (PCA) plate). The reduction in the enteric bacteria count following treatment with one or

12

more of: a salt and/or sugar solution; a probiotic solution; and/or an enzyme solution can be, for example, a reduction of greater than about 80%, greater than about 85%, greater than about 90%, greater than about 92%, greater than about 95%, or greater than about 96%, based on total bacterial counts (obtained, e.g., by taking colony forming units/gram of a treated tobacco sample, dividing it by colony forming units/gram of an untreated tobacco sample, subtracting the resulting number from 1, and multiplying by 100).

In certain embodiments, treatment as described herein provides a modified Lactobacillus bacteria count and, specifically, may provide an overall increase in Lactobacillus bacteria count. Lactobacillus counts can be obtained, for example, using the count method described above on a medium specific for lactobacillus (e.g., deMan Rogosa and Sharpe (MRS) medium). The MRS medium may allow for the growth of certain other types of bacteria in addition to Lactobacilli and thus "modified lactobacillus bacteria count" in certain embodiments refers to a count of all bacteria that grows on MRS media under anaerobic conditions, e.g., which in addition to Lactobacilli may include Leuconostoc and Pediococcus. The increase in the Lactobacillus bacteria count following treatment with one or more of: a salt and/or sugar solution; a probiotic solution; and/or an enzyme solution can be, for example, an increase of greater than about 50%, greater than about 100%, greater than about 150%, greater than about 200%, greater than about 300%, or greater than about 400%, based on total bacterial counts (obtained, e.g., by taking colony forming units/gram of a treated tobacco sample, dividing it by colony forming units/gram of an untreated tobacco sample, subtracting the resulting number from 1, and multiplying by 100). It is noted that, although an increase in Lactobacillus count is desirable in certain embodiments, some treatments result in a decrease in Lactobacillus count (e.g., providing a reduction in Lactobacillus count of treated tobacco of between about 0% and about 50% in some embodiments).

Different treatments can have different effects on the levels of various bacteria present within the tobacco plant material. As noted above, the treatment described herein may affect the properties of the treated tobacco and may be particularly beneficial to modify the content of certain bacteria prior to curing the treated tobacco. The pre-cure treatment disclosed herein can, in some embodiments, have further implications for later processing steps.

In the production of tobacco products, tobacco material is often cured and/or aged in order to convert the tobacco to a consumable form. Curing may comprise, for example, putting harvested tobacco material in an enclosure (e.g., a barn), under conditions allowing for oxidation and degradation of certain tobacco components. Curing typically dries the tobacco and commonly results in changes to the overall chemistry of the tobacco.

Examples of methods for curing and/or aging tobacco are discussed, for example, in U.S. Pat. No. 1,327,692 to Beinhart; U.S. Pat. No. 2,758,603 to Heljo; U.S. Pat. No. 5,676, 164 to Martin; U.S. Pat. No. 6,755,200 to Hempfling et al.; U.S. Pat. No. 7,293,564 to Perfetti et al., and U.S. Pat. No. 8,353,300 to Li et al.; and US Pat. Appl. Pub. Nos. 2010/0116281 and 2012/0279510 to Marshall et al., which are incorporated herein by reference in their entireties. Descriptions of further types of curing and aging processes for various types of tobacco are provided in Tobacco Production, Chemistry and Technology, Davis et al. (Eds.) (1999), which is also incorporated herein by reference.

For example, tobacco can be cured by methods including but not limited to, air-curing, dark air curing, sun-curing, fire

curing, and flue curing. Flue curing comprises curing tobacco in enclosures wherein flues heat cure the tobacco without exposing it to smoke and is described, for example, in Nestor et al., Beitrage Tabakforsch. Int., 20 (2003): 467-475 and U.S. Pat. No. 6,895,974 to Peele, which are both incorporated 5 herein by reference. Fire cured tobacco generally comprises curing tobacco in enclosures wherein it is exposed to the gaseous combustion products of a fire that is maintained at a low smolder and is described, for example, in US Pat. Appl. Publ. 2012/0125354 to Byrd et al., which is incorporated herein by reference. Air curing typically comprises hanging tobacco in a well-ventilated enclosure to dry at ambient conditions and is described, for example, in Roton et al., Beitrage Tabakforsch. Int. 21 (2005): 305-320; Staaf et al., Beitrage Tabakforsch Int. 21 (2005): 321-330; and U.S. Pat. No. 6,834, 15 654 to Williams, which are incorporated herein by reference. Sun curing generally comprises allowing tobacco to cure uncovered in the sun.

The tobacco material comprising modified bacteria levels (provided via treatment as described herein) can lead to modi- 20 fied levels of other types of compounds in the tobacco material after curing as compared with untreated tobacco material after curing. Such compounds may, in certain embodiments, be smoke toxicants and/or smoke toxicant precursors. For example, it is believed that certain compounds are produced, 25 at least in part, by the action of bacteria (e.g., gram negative bacteria) during the curing process. Specifically, bacteria can produce the enzyme nitrate reductase, which converts nitrates to nitrite and nitric oxide; nitric oxide can subsequently react with precursor tobacco alkaloids to produce tobacco-specific 30 nitrosamines (TSNAs). Exemplary TSNA compounds include N-nitrosonomicotine (NNN), 4-methyl-N-nitrosamino-1-(3-pyridyl)-1-butanone (NNK), N-nitrosoanatabine (NAT), 4-methyl-N-nitrosamino-1-(3-pyridyl)-1-butanol (NNAL), and N-nitrosoanabasine (NAB).

Although low levels of TSNA are typically observed in green tobacco material, it is generally understood that TSNAs are totaled during tobacco curing, fermentation, and/or aging processes. Consequently, various efforts to reduce TSNA levels by modifying the growth or curing process have been 40 attempted. See, for example, U.S. Pat. Nos. 4,343,317 and 4,347,859 to Bokelman; U.S. Pat. No. 5,803,081 to O'Donnell; U.S. Pat. No. 6,202,649 to Williams; U.S. Pat. No. 6,805,134 to Peele; U.S. Pat. No. 7,293,564 to Perfetti et al.; U.S. Pat. No. 7,404,406 to Peele; U.S. Pat. No. 8,353,300 45 to Li et al.; US Pat. Appl. Publ. No. 2012/0234334 to Chen et al.; PCT Appl. Publ. Nos. WO 83/01180 to Malik; WO 98/05226 and WO 98/58555 to Williams; and WO 01/35770 and WO 02/13636 to Hempfling et al., WO 03/094639 to Koga et al., and Müller et al., Molec. Gen. Genet. 161, 67-76 50 (1987), which are all incorporated herein by reference.

Accordingly, modifying the level of bacteria (e.g., gram negative bacteria) generally associated with tobacco material subjected to curing can, in some embodiments, lead to a cured tobacco material having a modified level of TSNAs (e.g., 55 fewer TSNAs by weight than in a comparable tobacco material that has not been treated prior to curing as described herein). In certain embodiments of the invention, the decrease in the level of TSNAs can vary but generally, a treated, cured tobacco will comprise between about 10% and about 90% by 60 weight of TSNAs generally as compared with the amount of TSNAs present in a comparable cured (but untreated) tobacco. For example, in certain embodiments, treated tobacco material may exhibit at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80% decrease in TSNA compounds by 65 weight after curing as compared with an untreated tobacco material after curing.

14

As described herein, treatment of a tobacco material with a treatment solution comprising a salt and/or sugar solution; a probiotic solution; and/or an enzyme solution can, in some embodiments, result in a modified (e.g., increased) number of *Lactobacillus* bacteria associated with the treated tobacco material relative to untreated tobacco material. This possible increase in *lactobacilli* associated with treatment of tobacco materials as described herein can, in some embodiments, have further beneficial effects. In certain embodiments (e.g., where tobacco material is being prepared for use in certain smokeless tobacco products), the tobacco material is cured and then fermented.

Fermentation generally requires subjecting the tobacco material to water (e.g., humidity) and heat. The fermentation process can be conducted in a chamber where the temperature and moisture content can be controlled. As a consequence of the elevated temperature and moisture content to which the tobacco is exposed during the fermentation process, certain components (e.g., ammonia) may be effectively removed from the tobacco. In some embodiments, fermentation is a bacterial process, wherein certain bacteria produce enzymes that react to produce flavor precursors within the fermenting tobacco material.

Exemplary fermentation processes for tobacco are provided in U.S. Pat. No. 2,927,188 to Brenik et al.; U.S. Pat. No. 4,660,577 to Sensabaugh et al.; U.S. Pat. No. 5,327,149 to Roth et al., which are incorporated herein by reference. Fermentation is enhanced by the presence of *Lactobacillus*; consequently, modification of the amount of *Lactobacillus* bacteria associated with a given tobacco sample can impact the fermentation of that tobacco sample. Where that treated tobacco is later subjected to fermentation, the fermentation can, in some embodiments, be enhanced by the presence of a greater number of *Lactobacillus* bacteria. By "enhanced" is meant that the fermentation process proceeds, for example, more quickly, and/or more uniformly.

Tobacco or tobaccos to which the method provided herein is applicable can vary. In certain embodiments, tobaccos that can be employed include flue-cured or Virginia (e.g., K326), burley, sun-cured (e.g., Indian Kurnool and Oriental tobaccos, including Katerini, Prelip, Komotini, Xanthi and Yambol tobaccos), Maryland, dark, dark-fired, dark air cured (e.g., Pasado, Cubano, Jatim and Bezuki tobaccos), light air cured (e.g., North Wisconsin and Galpao tobaccos), Indian air cured, Red Russian and Rustica tobaccos, as well as various other rare or specialty tobaccos and various blends of any of the foregoing tobaccos. Descriptions of various types of tobaccos, growing practices and harvesting practices are set forth in Tobacco Production, Chemistry and Technology, Davis et al. (Eds.) (1999), which is incorporated herein by reference. Various representative other types of plants from the Nicotiana species are set forth in Goodspeed, The Genus Nicotiana, (Chonica Botanica) (1954); U.S. Pat. No. 4,660, 577 to Sensabaugh, Jr. et al.; U.S. Pat. No. 5,387,416 to White et al. and U.S. Pat. No. 7,025,066 to Lawson et al.; US Patent Appl. Pub. Nos. 2006/0037623 to Lawrence, Jr. and 2008/ 0245377 to Marshall et al.; each of which is incorporated herein by reference. Exemplary *Nicotiana* species include *N*. tabacum, N. rustica, N. alata, N. arentsii, N. excelsior, N. forgetiana, N. glauca, N. glutinosa, N. gossei, N. kawakamii, N. knightiana, N. langsdorffi, N. otophora, N. setchelli, N. sylvestris, N. tomentosa, N. tomentosiformis, N. undulata, N. x sanderae, N. africana, N. amplexicaulis, N. benavidesii, N. bonariensis, N. debneyi, N. longiflora, N. maritina, N. megalosiphon, N. occidentalis, N. paniculata, N. plumbaginifolia, N. raimondii, N. rosulata, N. simulans, N. stocktonii, N. sua-

veolens, N. umbratica, N. velutina, N. wigandioides, N. acaulis, N. acuminata, N. attenuata, N. benthamiana, N. cavicola, N. clevelandii, N. cordifolia, N. corymbosa, N. fragrans, N. goodspeedii, N. linearis, N. miersii, N. nudicaulis, N. obtusifolia, N. occidentalis subsp. Hersperis, N. pauciflora, N. petunioides, N. quadrivalvis, N. repanda, N. rotundifolia, N. solanifolia, and N. spegazzinii.

Nicotiana species can be derived using genetic-modification or crossbreeding techniques (e.g., tobacco plants can be genetically engineered or crossbred to increase or decrease production of components, characteristics or attributes). See, for example, the types of genetic modifications of plants set forth in U.S. Pat. No. 5,539,093 to Fitzmaurice et al.; U.S. Pat. No. 5,668,295 to Wahab et al.; U.S. Pat. No. 5,705,624 to Fitzmaurice et al.; U.S. Pat. No. 5,844,119 to Weigl; U.S. Pat. No. 6,730,832 to Dominguez et al.; U.S. Pat. No. 7,173,170 to Liu et al.; U.S. Pat. No. 7,208,659 to Colliver et al. and U.S. Pat. No. 7,230,160 to Benning et al.; US Patent Appl. Pub. No. 2006/0236434 to Conkling et al.; and PCT WO 2008/103935 20 to Nielsen et al. See, also, the types of tobaccos that are set forth in U.S. Pat. No. 4,660,577 to Sensabaugh, Jr. et al.; U.S. Pat. No. 5,387,416 to White et al.; and U.S. Pat. No. 6,730, 832 to Dominguez et al., each of which is incorporated herein by reference. Most preferably, the tobacco materials are those 25 that have been appropriately cured and aged. Especially preferred techniques and conditions for curing flue-cured tobacco are set forth in Nestor et al., Beitrage Tabakforsch. Int., 20 (2003) 467-475 and U.S. Pat. No. 6,895,974 to Peele, which are incorporated herein by reference. Representative techniques and conditions for air curing tobacco are set forth in Roton et al., Beitrage Tabakforsch. Int., 21 (2005) 305-320 and Staaf et al., Beitrage Tabakforsch. Int., 21 (2005) 321-330, which are incorporated herein by reference. Certain types of unusual or rare tobaccos can be sun cured. Manners and methods for improving the smoking quality of Oriental tobaccos are set forth in U.S. Pat. No. 7,025,066 to Lawson et al., which is incorporated herein by reference. Representative Oriental tobaccos include katerini, prelip, komotini, xanthi 40 and vambol tobaccos. Tobacco compositions including dark air cured tobacco are set forth in US Patent Appl. Pub. No. 2008/0245377 to Marshall et al., which is incorporated herein by reference. See also, types of tobacco as set forth, for example, in US Patent Appl. Pub. No. 2011/0247640 to Bee- 45 son et al., which is incorporated herein by reference.

The Nicotiana species can be selected for the content of various compounds that are present therein. For example, in certain embodiments, plants of the Nicotiana species (e.g., Galpao commun tobacco) are specifically grown for their 50 abundance of leaf surface compounds. In certain embodiments, plants of the *Nicotiana* species are specifically grown for their relatively low levels of certain undesired compounds (e.g., asparagine). Tobacco plants can be grown in greenhouses, growth chambers, or outdoors in fields, or grown 55 a green form (e.g., the plant or portion thereof can be used hydroponically.

The means by which the treatment solutions described herein can be applied to the tobacco plant or plant material can vary. Certain methods to treat plants with a salt and/or sugar solution, probiotic solution, and/or an enzyme solution 60 which could be used or modified for use, in the present invention are provided in U.S. Pat. No. 4,140,136 to Geiss et al.; U.S. Pat. No. 4,151,848 to Newton et al.; U.S. Pat. No. 4,308, 877 to Mattina et al.; U.S. Pat. No. 4,476,881 to Gravely et al.; U.S. Pat. No. 4,556,073 to Gravely et al.; U.S. Pat. No. 4,557, 65 280 to Gravely et al.; U.S. Pat. No. 4,566,469 to Semp et al.; U.S. Pat. No. 5,372,149 to Roth et al.; U.S. Pat. No. 7,549,425

16

to Koga et al.; U.S. Pat. No. 7,549,426 to Koga et al.; and U.S. Pat. No. 7,556,046 to Koga et al., all of which are incorporated herein by reference.

The method of application of the treatment solution as disclosed herein will often depend, at least in part, on the stage of the tobacco plant. For example, in certain embodiments, the salt and/or sugar solution; probiotic solution; and/ or enzyme solution are applied to a tobacco seed prior to planting. In such embodiments, the treatment solution can be applied in the form of a seed treatment or coating. For example, the seeds can be dipped in such a solution, soaked in the solution, or sprayed with the solution. In certain embodiments, the solution can be applied to a tobacco in seedling or unharvested (live) plant form or may be applied to the soil in which the tobacco plants will be planted or are presently planted. In such embodiments, spray application of treatment solution can be used (e.g., using a hydraulic boom sprayer, air blast sprayer, sprinkler system, fogger, or aerial sprayer), although the method of application is not limited thereto. Certain methods to treat plants with microorganisms which could be used, or modified for use, in the present invention are provided in U.S. Pat. No. 4,140,136 to Geiss et al.; U.S. Pat. No. 4,151,848 to Newton et al.; U.S. Pat. No. 4,308,877 to Mattina et al.; U.S. Pat. No. 4,476,881 to Gravely et al.; U.S. Pat. No. 4,556,073 to Gravely et al.; U.S. Pat. No. 4,557,280 to Gravely et al.; U.S. Pat. No. 4,566,469 to Semp et al.; U.S. Pat. No. 5,372,149 to Roth et al.; U.S. Pat. No. 7,549,425 to Koga et al.; U.S. Pat. No. 7,549,426 to Koga et al.; and U.S. Pat. No. 7,556,046 to Koga et al., all of which are incorporated herein by reference.

Although it may be advantageous to apply the treatment (i.e., solution containing salt and/or sugar, probiotic(s), and/ or enzyme(s)) while the tobacco plant is still in living form, it is also possible in some embodiments to apply the treatment solution following harvesting of the tobacco plants. Such application can occur at any time following harvest, including immediately following harvest, prior to or following postharvest processing (e.g., drying, curing, and/or physical processing of the plant), or at any stage in between. Advantageously, the treatment is conducted prior to any significant curing of the tobacco plant material. The application of salt and/or sugar solution, probiotic solution, and/or enzyme solution can be done at one stage in the plant life cycle, or can be conducted at two or more stages.

The whole tobacco plant, or certain parts or portions of the plant of the Nicotiana species can be used and/or treated as provided herein. For example, virtually all of the plant (e.g., the whole plant) can be harvested and employed as such. Alternatively, various parts or pieces of the plant can be harvested or separated for treatment after harvest. For example, the flower, leaves, stem, stalk, roots, seeds, and various combinations thereof, can be isolated for use or fur-

After treatment, the treated tobacco material can be used in without being subjected to any curing process). For example, the plant or portion thereof can be used without being subjected to significant storage, handling or processing conditions. In certain situations, it is advantageous for the plant or portion thereof be used virtually immediately after harvest. Alternatively, for example, a plant or portion thereof in green form can be refrigerated or frozen for later use, freeze dried, subjected to irradiation, yellowed, dried, cured (e.g., using air drying techniques or techniques that employ application of heat), heated or cooked (e.g., roasted, fried or boiled), or otherwise subjected to storage or treatment for later use. It is understood that the benefits, e.g., reduced TSNA formation,

enhanced fermentation, and the like, are realized after curing; therefore, the treated materials described herein are advantageously cured prior to use, e.g., in a tobacco product.

The tobacco material can be physically processed (before or after treatment and before or after curing). The plant or 5 portion thereof can be separated into individual parts or pieces (e.g., the leaves can be removed from the stems, and/or the stems and leaves can be removed from the stalk). The harvested plant or individual parts or pieces can be further subdivided into parts or pieces (e.g., the leaves can be shredded, cut, comminuted, pulverized, milled or ground into pieces or parts that can be characterized as filler-type pieces, granules, particulates or fine powders). The tobacco material can have the form of processed tobacco parts or pieces, cured and aged tobacco in essentially natural lamina and/or stem 15 form, a tobacco extract, extracted tobacco pulp (e.g., using water as a solvent), or a mixture of the foregoing (e.g., a mixture that combines extracted tobacco pulp with granulated cured and aged natural tobacco lamina). The tobacco that is used for the tobacco product most preferably includes 20 tobacco lamina, or a tobacco lamina and stem mixture. Portions of the tobaccos within the tobacco product may have processed forms, such as processed tobacco stems (e.g., cutrolled stems, cut-rolled-expanded stems or cut-puffed stems), or volume expanded tobacco (e.g., puffed tobacco, such as 25 dry ice expanded tobacco (DIET)). See, for example, the tobacco expansion processes set forth in U.S. Pat. No. 4,340, 073 to de la Burde et al.; U.S. Pat. No. 5,259,403 to Guy et al.; and U.S. Pat. No. 5,908,032 to Poindexter, et al.; and U.S. Pat. No. 7,556,047 to Poindexter, et al., all of which are incorporated by reference. In addition, the tobacco product optionally may incorporate tobacco that has been fermented. See, also, the types of tobacco processing techniques set forth in PCT WO 05/063060 to Atchley et al., which is incorporated herein by reference.

The manner by which the tobacco is provided in such forms can vary. The plant, or parts thereof, can be subjected to external forces or pressure (e.g., by being pressed or subjected to roll treatment). When carrying out such processing conditions, the plant or portion thereof can have a moisture 40 content that approximates its natural moisture content (e.g., its moisture content immediately upon harvest), a moisture content achieved by adding moisture to the plant or portion thereof, or a moisture content that results from the drying of the plant or portion thereof. For example, powdered, pulver- 45 ized, ground or milled pieces of plants or portions thereof can have moisture contents of less than about 25 weight percent. often less than about 20 weight percent, and frequently less than about 15 weight percent. Tobacco parts or pieces can be comminuted, ground or pulverized into a powder type of form 50 using equipment and techniques for grinding, milling, or the like. Most preferably, the tobacco is relatively dry in form during grinding or milling, using equipment such as hammer mills, cutter heads, air control mills, or the like. For example, tobacco parts or pieces may be ground or milled when the 55 moisture content thereof is less than about 15 weight percent to less than about 5 weight percent.

Tobacco compositions intended to be used in a smokable or smokeless form may incorporate a single type of tobacco (e.g., in a so-called "straight grade" form). For example, the 60 tobacco within a tobacco composition may be composed solely of flue-cured tobacco (e.g., all of the tobacco may be composed, or derived from, either flue-cured tobacco lamina or a mixture of flue-cured tobacco lamina and flue-cured tobacco stem. The tobacco within a tobacco composition also 65 may have a so-called "blended" form. For example, the tobacco within a tobacco composition of the present inven-

18

tion may include a mixture of parts or pieces of flue-cured, burley (e.g., Malawi burley tobacco) and Oriental tobaccos (e.g., as tobacco composed of, or derived from, tobacco lamina, or a mixture of tobacco lamina and tobacco stem). For example, a representative blend may incorporate about 30 to about 70 parts burley tobacco (e.g., lamina, or lamina and stem), and about 30 to about 70 parts flue cured tobacco (e.g., stem, lamina, or lamina and stem) on a dry weight basis. Other exemplary tobacco blends incorporate about 75 parts flue-cured tobacco, about 15 parts burley tobacco, and about 10 parts Oriental tobacco; or about 65 parts flue-cured tobacco, about 25 parts burley tobacco, and about 10 parts Oriental tobacco; or about 65 parts flue-cured tobacco, about 10 parts burley tobacco, and about 25 parts Oriental tobacco; on a dry weight basis. Other exemplary tobacco blends incorporate about 20 to about 30 parts Oriental tobacco and about 70 to about 80 parts flue-cured tobacco.

Tobacco that has been treated according to the present disclosure can, in certain embodiments, be subsequently extracted. Various extraction techniques can be used. See, for example, the extraction processes described in US Pat. Appl. Pub. No. 2011/0247640 to Beeson et al., which is incorporated herein by reference. Other exemplary techniques for extracting components of tobacco are described in U.S. Pat. No. 4,144,895 to Fiore; U.S. Pat. No. 4,150,677 to Osborne, Jr. et al.; U.S. Pat. No. 4,267,847 to Reid; U.S. Pat. No. 4,289,147 to Wildman et al.; U.S. Pat. No. 4,351,346 to Brummer et al.; U.S. Pat. No. 4,359,059 to Brummer et al.; U.S. Pat. No. 4,506,682 to Muller; U.S. Pat. No. 4,589,428 to Keritsis; U.S. Pat. No. 4,605,016 to Soga et al.; U.S. Pat. No. 4,716,911 to Poulose et al.; U.S. Pat. No. 4,727,889 to Niven, Jr. et al.; U.S. Pat. No. 4,887,618 to Bemasek et al.; U.S. Pat. No. 4,941,484 to Clapp et al.; U.S. Pat. No. 4,967,771 to Fagg et al.; U.S. Pat. No. 4,986,286 to Roberts et al.; U.S. Pat. No. 5,005,593 to Fagg et al.; U.S. Pat. No. 5,018,540 to Grubbs et al.; U.S. Pat. No. 5.060,669 to White et al.; U.S. Pat. No. 5,065,775 to Fagg; U.S. Pat. No. 5,074,319 to White et al.; U.S. Pat. No. 5.099,862 to White et al.: U.S. Pat. No. 5.121, 757 to White et al.; U.S. Pat. No. 5,131,414 to Fagg; U.S. Pat. No. 5,131,415 to Munoz et al.; U.S. Pat. No. 5,148,819 to Fagg; U.S. Pat. No. 5,197,494 to Kramer; U.S. Pat. No. 5,230, 354 to Smith et al.; U.S. Pat. No. 5,234,008 to Fagg; U.S. Pat. No. 5,243,999 to Smith; U.S. Pat. No. 5,301,694 to Raymond et al.; U.S. Pat. No. 5,318,050 to Gonzalez-Parra et al.; U.S. Pat. No. 5,343,879 to Teague; U.S. Pat. No. 5,360,022 to Newton; U.S. Pat. No. 5,435,325 to Clapp et al.; U.S. Pat. No. 5,445,169 to Brinkley et al.; U.S. Pat. No. 6,131,584 to Lauterbach; U.S. Pat. No. 6,298,859 to Kierulff et al.; U.S. Pat. No. 6,772,767 to Mua et al.; and U.S. Pat. No. 7,337,782 to Thompson, all of which are incorporated by reference herein.

The tobacco materials discussed in the present invention can further be treated and/or processed in other ways before, after, or during the enzymatic treatment described herein. For example, if desired, the tobacco materials can be irradiated, pasteurized, or otherwise subjected to controlled heat treatment. Such treatment processes are detailed, for example, in US Pat. Pub. No. 2009/0025738 to Mua et al., which is incorporated herein by reference. It is noted that, advantageously, in embodiments wherein the treatment solution comprises an enzyme, the enzyme is at least about 75%, at least about 80%, at least about 98%, at least about 99%, or completely deactivated and/or degraded at elevated temperatures. Therefore, in certain embodiment, where the enzyme-treated tobacco is heat-treated and/or used at an elevated temperature (e.g.,

incorporated within a cigarette, which burns at an elevated temperature), little to no active enzyme may remain in the tobacco material.

In certain embodiments, treated tobacco materials as described herein can be further contacted with water and an 5 additive capable of inhibiting reaction of asparagine to form acrylamide upon heating of the tobacco material (e.g., an additive selected from the group consisting of lysine, glycine, histidine, alanine, methionine, glutamic acid, aspartic acid, proline, phenylalanine, valine, arginine, compositions incor- 10 porating di- and trivalent cations, asparaginase, certain nonreducing saccharides, certain reducing agents, phenolic compounds, certain compounds having at least one free thiol group or functionality, oxidizing agents, oxidation catalysts, natural plant extracts (e.g., rosemary extract), and combina- 15 tions thereof), and combinations thereof. See, for example, the types of treatment processes described in US Pat. Pub. Nos. 2010/0300463; 2011/0048434; and 2012/0060854, all to Chen et al., which are all incorporated herein by reference. In certain embodiments, this type of treatment is useful where 20 the original tobacco material is subjected to heat in the extraction and/or distillation process previously described.

The treated tobacco can be incorporated within various types of tobacco products according to the present invention. For example, in some embodiments, the invention provides 25 smoking articles, such as cigarettes, that comprise a treated tobacco material that has been subjected to one or more of the types of treatment described herein. Referring to FIG. 1, there is shown a smoking article 10 in the form of a cigarette and possessing certain representative components of a smoking article of the present invention. The cigarette 10 includes a generally cylindrical rod 12 of a charge or roll of smokable filler material (e.g., about 0.3 to about 1.0 g of smokable filler material such as tobacco material treated as described herein) contained in a circumscribing wrapping material 16. The rod 35 12 is conventionally referred to as a "tobacco rod." The ends of the tobacco rod 12 are open to expose the smokable filler material. The cigarette 10 is shown as having one optional band 22 (e.g., a printed coating including a film-forming agent, such as starch, ethylcellulose, or sodium alginate) 40 applied to the wrapping material 16, and that band circumscribes the cigarette rod in a direction transverse to the longitudinal axis of the cigarette. That is, the band 22 provides a cross-directional region relative to the longitudinal axis of the cigarette. The band 22 can be printed on the inner surface of 45 the wrapping material (i.e., facing the smokable filler material), or less preferably, on the outer surface of the wrapping material. Although the cigarette can possess a wrapping material having one optional band, the cigarette also can possess wrapping material having further optional spaced bands num- 50 bering two, three, or more.

At one end of the tobacco rod 12 is the lighting end 18, and at the mouth end 20 is positioned a filter element 26. The filter element 26 positioned adjacent one end of the tobacco rod 12 such that the filter element and tobacco rod are axially aligned 55 in an end-to-end relationship, preferably abutting one another. Filter element 26 may have a generally cylindrical shape, and the diameter thereof may be essentially equal to the diameter of the tobacco rod. The ends of the filter element 26 permit the passage of air and smoke therethrough.

A ventilated or air diluted smoking article can be provided with an optional air dilution means, such as a series of perforations 30, each of which extend through the plug wrap 28. The optional perforations 30 can be made by various techniques known to those of ordinary skill in the art, such as laser 65 perforation techniques. Alternatively, so-called off-line air dilution techniques can be used (e.g., through the use of

20

porous paper plug wrap and pre-perforated tipping paper). The filter element 26 is circumscribed along its outer circumference or longitudinal periphery by a layer of outer plug wrap 28. During use, the smoker lights the lighting end 18 of the cigarette 10 using a match or cigarette lighter. As such, the smokable material 12 begins to burn. The mouth end 20 of the cigarette 10 is placed in the lips of the smoker. Thermal decomposition products (e.g., components of tobacco smoke) generated by the burning smokable material 12 are drawn through the cigarette 10, through the filter element 26, and into the mouth of the smoker.

In certain embodiments, according to the invention, a smoking article comprises tobacco that has been treated as described herein (i.e., treated pre-curing with one or more of a salt and/or sugar solution; a probiotic solution; and/or an enzyme solution). The tobacco within the smoking article can, in some embodiments, comprise only such treated tobacco or can contain varying amounts of treated tobacco in combination with other tobacco materials. For example, the treated tobacco can be present in an amount of about 25% or more, about 50% or more, about 75% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, or about 100% based on the weight of all tobacco material in the smoking article. Advantageously, in some embodiments, the salt, sugar, enzyme, and/or probiotic used in the treatment of tobacco materials is not transferred in smoke produced from a cigarette made with such tobacco.

Referring to FIG. 2, a representative snus type of tobacco product comprising treated tobacco as described herein (i.e., tobacco treated with one or more of a salt and/or sugar solution; a probiotic solution; and/or an enzyme solution) is shown. In particular, FIG. 2 illustrates a smokeless tobacco product 40 having a water-permeable outer pouch 42 containing a smokeless tobacco composition 44, wherein the tobacco composition includes a shredded or particulate tobacco material that has been treated as described herein. Further additives can be admixed with, or otherwise incorporated within, the smokeless tobacco compositions according to the invention. The additives can be artificial, or can be obtained or derived from herbal or biological sources. Exemplary types of additives include salts (e.g., sodium chloride, potassium chloride, sodium citrate, potassium citrate, sodium acetate, potassium acetate, and the like), natural sweeteners (e.g., fructose, sucrose, glucose, maltose, vanillin, ethylvanillin glucoside, mannose, galactose, lactose, and the like), artificial sweeteners (e.g., sucralose, saccharin, aspartame, acesulfame K, neotame and the like), organic and inorganic fillers (e.g., grains, processed grains, puffed grains, maltodextrin, dextrose, calcium carbonate, calcium phosphate, corn starch, lactose, manitol, xylitol, sorbitol, finely divided cellulose, and the like), binders (e.g., povidone, sodium carboxymethylcellulose and other modified cellulosic types of binders, sodium alginate, xanthan gum, starch-based binders, gum arabic, lecithin, and the like), pH adjusters or buffering agents (e.g., metal hydroxides, preferably alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, and other alkali metal buffers such as metal carbonates, preferably potassium carbonate or sodium carbonate, or metal bicarbonates such as sodium bicarbonate, and the like), colo-60 rants (e.g., dyes and pigments, including caramel coloring and titanium dioxide, and the like), humectants (e.g., glycerin, propylene glycol, and the like), oral care additives (e.g., thyme oil, eucalyptus oil, and zinc), preservatives (e.g., potassium sorbate, and the like), syrups (e.g., honey, high fructose corn syrup, and the like), disintegration aids (e.g., microcrystalline cellulose, croscarmellose sodium, crospovidone, sodium starch glycolate, pregelatinized corn starch, and the

like), flavorant and flavoring mixtures, antioxidants, and mixtures thereof. If desired, the additive can be microencapsulated as set forth in US Patent Appl. Pub. No. 2008/0029110 to Dube et al., which is incorporated by reference herein. In addition, exemplary encapsulated additives are described, for 5 example, in WO 2010/132444 A2 to Atchley, which has been previously incorporated by reference herein.

EXPERIMENTAL

The present invention is more fully illustrated by the following example, which is set forth to illustrate the present invention and is not to be construed as limiting thereof. Unless otherwise noted, all parts and percentages are by weight, and all weight percentages are expressed on a dry 15 basis, meaning excluding water content, unless otherwise

Dark-air cured tobacco is treated five hours prior to harvest with one or more of a probiotic bacteria solution, and enzyme solution, and/or a 3% sodium chloride salt solution. The 20 solution is applied using a backpack sprayer. Solutions are based on a 100 gallon solution per acre, using recommended plant spacings and dose per plant is provided below.

The treated tobacco is harvested and mid-stalk leaf samples are analyzed for total bacteria counts, enteric bacte- 25 ria counts, and Lactobacillus counts. Ten grams of each treated tobacco sample is placed in Butterfields Phosphate Buffer and diluted 10^{-2} to 10^{-8} times with water. The treated tobacco sample dilutions are applied to plate count agar (PCA) for total aerobic bacteria counts, to violet red bile agar 30 (VRBA) for gram negative bacteria counts, and to MRS for anaerobic (Lactobacillus) counts. The number of bacterial colonies, as visualized under magnification, are counted to estimate the total number of colony-forming units per gram, CFU/g.

Tobacco treated with a probiotic solution available from CVS (solution prepared to provide 6.00×10⁹ CFU per plant) exhibited a total bacteria reduction after treatment of 91%, an enteric bacteria reduction after treatment of 40%, and a Lactobacillus reduction after treatment of 46% (all based on total 40 bacteria counts before and after treatment).

Tobacco treated with a probiotic solution available from Walgreens (solution prepared to provide 6.40×10⁹ CFU per plant) exhibited a total bacteria reduction after treatment of 96%, an enteric bacteria reduction after treatment of 58%, 45 and a Lactobacillus reduction after treatment of 42% (all based on total bacteria counts before and after treatment).

Tobacco treated with a probiotic solution available from CVS (solution prepared to provide 6.00×10^9 CFU per plant) in combination with a surfactant (Surf-Ace® from Drexel 50 Chemical Company) exhibited a total bacteria reduction after treatment of 95%, an enteric bacteria reduction after treatment of 66%, and a Lactobacillus increase after treatment of 57% (all based on total bacteria counts before and after treat-

Tobacco treated with a Lactobacillus plantarum probiotic solution (solution prepared to provide 6.64×10¹⁰ CFU per plant) exhibited a total bacteria reduction after treatment of 95%, an enteric bacteria reduction after treatment of 75%, on total bacteria counts before and after treatment).

Tobacco treated with a Lactobacillus acidophilus probiotic solution (solution prepared to provide 2.72×10¹⁰ CFU per plant) exhibited a total bacteria reduction after treatment of 93%, an enteric bacteria reduction after treatment of 20%, 65 and a Lactobacillus reduction after treatment of 33% (all based on total bacteria counts before and after treatment).

22

Tobacco treated with a Bifidobacterium lactis probiotic solution (solution prepared to provide 4.16×10¹⁰ CFU per plant) exhibited a total bacteria reduction after treatment of 82%, an enteric bacteria reduction after treatment of 25%, and a Lactobacillus reduction after treatment of 16% (all based on total bacteria counts before and after treatment).

Tobacco treated with a Lactobacillus helveticus probiotic solution (solution prepared to provide 5.20×10⁹ CFU per plant) exhibited a total bacteria reduction after treatment of 97%, an enteric bacteria reduction after treatment of 39%, and a Lactobacillus increase after treatment of greater than 400% (all based on total bacteria counts before and after treatment).

Tobacco treated with a PreventASeTM enzyme solution (solution prepared to provide 3.2 mL asparaginase per plant) exhibited a total bacteria reduction after treatment of 88%, an enteric bacteria reduction after treatment of 75%, and a Lactobacillus reduction after treatment of 43% (all based on total bacteria counts before and after treatment).

Tobacco treated with a 3% NaCl solution exhibited a total bacteria reduction after treatment of 94%, an enteric bacteria reduction after treatment of 76%, and a Lactobacillus increase after treatment of greater than 400% (all based on total bacteria counts before and after treatment).

The data illustrates that all treatment solutions provided in a decrease in total bacteria associated with the treated tobacco material (as compared with the tobacco material prior to treatment). The salt (NaCl)-treated tobacco material exhibited a significant increase in desirable *Lactobacillus* bacteria. This finding may render such NaCl (and other salt)-treated tobacco materials particularly suitable for further fermentation processes and for incorporation of such fermented tobacco materials into smokeless tobacco products. Additionally, the Lactobacillus helveticus-treated tobacco material 35 exhibited a substantial increase in Lactobacillus bacteria after treatment. Although some increase might be expected due to the presence of Lactobacillus bacteria in the treatment solution, the increase is much higher than that noted for other Lactobacillus probiotic solution-treated tobacco materials (e.g., tobacco treated with Lactobacillus plantarum exhibited only a 43% increase and tobacco treated with Lactobacillus acidophilus exhibited a 33% decrease in Lactobacillus bacteria). Consequently, Lactobacillus helveticus-treated tobacco materials may be particularly well suited for further fermentation processes and incorporation of such fermented tobacco materials into smokeless tobacco products as well.

Many modifications and other embodiments of the invention will come to mind to one skilled in the art to which this invention pertains having the benefit of the teachings presented in the foregoing description. Therefore, it is to be understood that the invention is not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed 55 herein, they are used in a generic and descriptive sense only and not for purposes of limitation.

What is claimed:

1. A method of modifying the bacterial content of a tobacco and a Lactobacillus increase after treatment of 43% (all based 60 material, comprising contacting an unharvested tobacco material less than about 24 hours before harvest with a treatment solution, wherein the treatment solution is selected from the group consisting of: (i) a solution comprising salt, sugar, or a combination thereof, wherein the salt is selected from the group consisting of NaCl, CaCl2, MgCl2, KCl, and combinations thereof; (ii) a solution comprising one or more enzymes; and (iii) a solution comprising one or more probiotic Lacto-

23

bacillus bacteria, wherein said contacting provides a treated tobacco material having a reduced total bacterial content following harvest.

- 2. The method of claim 1, wherein the unharvested tobacco material is selected from the group consisting of a tobacco seed, a tobacco seedling, an immature live plant, a mature live plant, or a portion thereof.
- 3. The method of claim 1, wherein the total bacterial content of the treated tobacco material is reduced by at least about 50% in number following harvest.
- **4**. The method of claim **1**, wherein the total bacterial content of the treated tobacco material is reduced by at least about 80% in number following harvest.
- 5. The method of claim 1, wherein the total bacterial content of the tobacco material comprises Gram-negative bacteria and wherein the Gram-negative bacterial content of the treated tobacco material is reduced by at least about 50% in number following harvest.
- **6**. The method of claim **1**, wherein the total bacterial content of the tobacco material comprises bacteria of the *Lactobacillus* genus, and wherein the *Lactobacillus* bacterial content of the treated tobacco material is increased following barvest
- 7. The method of claim 1, wherein the treatment solution comprises NaCl.
- **8**. The method of claim **1**, wherein the treatment solution has a concentration of salt, sugar, or a combination thereof of between about 1 and about 4 percent by weight.
- **9**. The method of claim **1**, wherein the treatment solution comprises *Lactobacillus helveticus*.
- 10. The method of claim 1, wherein the treatment solution has a concentration of probiotic bacteria of between about 1×10^5 colony forming units/mL and about 1×10^{10} colony forming units/mL.
- 11. The method of claim 1, wherein the treatment solution 35 has a concentration of enzyme of between about 10 AU and about 50,000 AU per plant.
- 12. The method of claim 1, wherein the treatment solution further comprises a surfactant.
- 13. The method of claim 1, further comprising curing the treated tobacco material to give a treated, cured tobacco material
- 14. The method of claim 13, wherein the tobacco-specific nitrosamine content of the treated, cured tobacco material is reduced relative to an untreated, cured tobacco material.
- 15. The method of claim 13, further comprising subjecting the treated, cured tobacco material to fermentation, wherein the fermentation is completed in less time than that required for fermentation of untreated, cured tobacco material.
 - 16. The method of claim 13, further comprising: processing the treated, cured tobacco material to provide a processed tobacco material in a form suitable for incorporation in a tobacco product; and

incorporating the processed tobacco material into a smokeless tobacco product or a smoking article.

- 17. The method of claim 16, wherein the processed tobacco material is in the form of cut filler.
- **18**. The method of claim **16**, wherein the processed tobacco material is in the form of a tobacco blend.
- 19. The method of claim 16, wherein the smoking article, ⁶⁰ upon smoking, is characterized by a TSNA content of mainstream smoke that is reduced relative to an untreated control smoking article.

24

20. The method of claim 1, comprising contacting an unharvested tobacco material with a solution containing salt to give a treated tobacco material;

harvesting and curing the treated tobacco material; subjecting the cured tobacco material to fermentation; and incorporating the fermented tobacco material into a smokeless tobacco product.

21. A method of modifying the bacterial content of a tobacco material, comprising:

contacting an unharvested tobacco material less than about 24 hours before harvest with a salt solution comprising NaCl in a concentration of about 0.5% to about 15% by weight of the treatment solution, wherein said contacting provides a treated tobacco material having a reduced total bacterial content following harvest;

harvesting the treated tobacco material; and

curing the harvested, treated tobacco material to give a treated, cured tobacco material.

- 22. The method of claim 21, wherein the unharvested tobacco material is selected from the group consisting of a tobacco seed, a tobacco seedling, an immature live plant, a mature live plant, or a portion thereof.
- 23. The method of claim 21, wherein the total bacterial content of the treated tobacco material is reduced by at least about 50% in number following harvest.
- 24. The method of claim 21, wherein the total bacterial content of the tobacco material comprises bacteria of the *Lactobacillus* genus, and wherein the *Lactobacillus* bacterial content of the treated tobacco material is increased following harvest.

25. The method of claim 21, further comprising:

processing the treated, cured tobacco material to provide a processed tobacco material in a form suitable for incorporation in a tobacco product; and

incorporating the processed tobacco material into a smokeless tobacco product or a smoking article.

26. The method of claim 21, further comprising:

subjecting the treated, cured tobacco material to fermentation; and

incorporating the fermented tobacco material into a smokeless tobacco product.

- 27. A method of modifying the bacterial content of a tobacco material, comprising contacting an unharvested tobacco material with a treatment solution comprising one or more probiotic *Lactobacillus* bacteria, wherein said contacting provides a treated tobacco material having a reduced total bacterial content following harvest.
- 28. The method of claim 27, wherein the total bacterial content of the treated tobacco material is reduced by at least about 50% in number following harvest.
- 29. The method of claim 27, wherein the treatment solution comprises *Lactobacillus helveticus*.
- 30. The method of claim 27, wherein the treatment solution has a concentration of probiotic *Lactobacillus* bacteria of between about 1×10^5 colony forming units/mL and about 1×10^{10} colony forming units/mL.
- 31. The method of claim 27, further comprising curing the treated tobacco material to give a treated, cured tobacco material
- **32**. The method of claim **31**, wherein the tobacco-specific nitrosamine content of the treated, cured tobacco material is reduced relative to an untreated, cured tobacco material.

* * * * *